Joshua Zeidner/ X ; Daniel Peters/ X
Jul 13, 2026, 10:49
Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
Joshua Zeidner, Professor of Medicine at The University of North Carolina at Chapel Hill, shared Daniel Peters‘s post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting!
Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN.
Study for newly diagnosed younger/fit KMT2Ar AML.”
Daniel Peters, Assistant Professor at Medical College of Georgia at Augusta University and Member of the Georgia Cancer Center, shared a post on X:
“One of the many great talks at MD Education AML-ALL focus group.
Joshua Zeidner at UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos.
Tip of the iceberg!”
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment